This page features news and updates related to medicinal cannabis. For more general information and resources, see Medicinal cannabis.
News and updates
31 October 2022
West Australian health practitioner fined $13,320 for alleged unlawful advertising of medicinal cannabis
The TGA has issued infringement notices for the alleged unlawful advertising of medicinal cannabis products on a website and through social media.
31 October 2022
Two medicinal cannabis clinics fined $239,760 for alleged unlawful advertising
The TGA has issued infringement notices for the alleged unlawful advertising of medicinal cannabis products on their websites and social media platforms.
22 December 2021
SA individual fined $7,992 for alleged unlawful advertising of medicinal cannabis
The TGA has issued three infringement notices, totalling $7,992, to an individual from South Australia for allegedly advertising medicinal cannabis in breach of the Therapeutic Goods Act 1989.
27 September 2022
Three medicinal cannabis companies fined almost $1 million for alleged unlawful advertising
The TGA has issued 73 infringement notices totalling $972,360 to licensed medicinal cannabis companies, MGC Pharmaceuticals Ltd (23 notices, $306,360) Cannatrek Ltd (22 notices, $293,040) and Little Green Pharma Ltd (28 notices, $372,960) for the alleged unlawful advertising of medicinal cannabis products on their websites and social media platforms.
17 December 2021
Commcare (WA) Pty Ltd (St Francis Pharmacy) fined $39,960 for alleged advertising breaches relating to medicinal cannabis
The TGA has issued three infringement notices totalling $39,960 for alleged unlawful advertising of medicinal cannabis in breach of the Therapeutic Goods Act 1989.
28 September 2021
Individual fined $18,648 for alleged advertising breaches relating to medicinal cannabis products
The TGA has issued seven infringement notices totalling $18,648 to the individual responsible for the Invigorate Labs website, for alleged breaches that relate to the advertising of products containing cannabidiol (CBD).
3 May 2021
Reminder: supply and advertising controls on medicinal cannabis
The TGA is reminding businesses involved with medicinal cannabis products of their regulatory obligations under the Therapeutic Goods Act 1989.
3 May 2021
TGA warns consumers about potential harm from unlawfully supplied medicinal cannabis
The TGA is warning consumers about the risks of buying medicinal cannabis products online.
13 April 2021
Supply and wholesaling of medicinal cannabis products (MCP)
Guidance for those who import or manufacture medicinal cannabis products.
4 March 2021
Australian Government response to the Senate Community Affairs References Committee report: Inquiry into current barriers to patient access to medicinal cannabis in Australia
The Australian Government response to the to the Senate Community Affairs References Committee report: Inquiry into current barriers to patient access to medicinal cannabis in Australia was published on 4 March 2021 on the Office of Drug Control website.
18 September 2020
Testing of medicinal cannabis products being supplied via SAS in Australia
The TGA has released a report summarising the recent laboratory testing of medicinal cannabis products.
9 September 2020
Notice of interim decisions on proposed amendments to the Poisons Standard - ACMS and Joint ACMS-ACCS meetings, June 2020
Interim decisions and invitation for further comment, including in relation to cannabidiol (private application) and cannabidiol (delegate initiated). Closing date: 13 October 2020.
23 June 2020
TGA to review complaints of alleged non-compliant advertising of medicinal cannabis products to the public
The Therapeutic Goods Administration (TGA) has commenced a review of complaints received alleging non-compliant advertising of medicinal cannabis products to the public.
24 April 2020
Consultation: Proposed amendments to the Poisons Standard - Joint ACMS/ACCS meetings, June 2020
This consultation is for a delegate initiated proposal to amend the scheduling for cannabidiol.
24 April 2020
Review on the safety of low dose cannabidiol
The aim of this review was to assess the current clinical literature to investigate the safety of low doses of CBD and what low dose ranges are used in research studies. It also sought to determine if the safety profile and characteristics of the low dose CBD lends itself to consideration for down scheduling.
31 August 2016
Scheduling delegate’s final decisions: Cannabis and tetrahydrocannabinols
The delegate's final decision and reasons relating to a scheduling proposal for cannabis and tetrahydrocannabinols.